We're proud to receive a 2025 CDMO Leadership Award in the “Small Molecule Dosage Form - Global" category.
The Challenge: A new United States-based biopharma working on its first cell therapy-based treatment had expanded the scope of their trial and extended its patient pool to include a patient in Beijing, China.
Download this case study to learn how they addressed the challenges of: